Logo

Aveo Entered into an Clinical Trial Collaboration and Supply Agreement with Eli Lilly to Evaluate Ficlatuzumab + Erbitux (cetuximab) for HNSCC in North America

Share this
Aveo Entered into an Clinical Trial Collaboration and Supply Agreement with Eli Lilly to Evaluate Ficlatuzumab + Erbitux (cetuximab) for HNSCC in North America

Aveo Entered into an Clinical Trial Collaboration and Supply Agreement with Eli Lilly to Evaluate Ficlatuzumab + Erbitux (cetuximab) for HNSCC in North America

Shots:

  • The company collaborated to evaluate ficlatuzumab + cetuximab in the P-III registrational trial for patients with HPV- R/M HNSCC. The trial is expected to be initiated in H1’23
  • AVEO had entered into a similar deal with Merck KGaA to supply cetuximab outside of the US & Canada. In the recent agreement, Lilly will be responsible to provide cetuximab clinical drug supply in the same country while AVEO will serve as the study sponsor and will be responsible for trial execution
  • Ficlatuzumab + cetuximab showed a superior ORR including 2 patients with CR rate & m-PFS superior to historical data for current SoC. The combination therapy has the potential to be an imp. therapy option for HPV- R/M HNSCC, based on P-II trial results

Ref: Globenewswire | Image: Aveo Oncology

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions